Limits...
Effect of deamino-8-D-arginine desmopressin in uremic bleeding.

Hong SY, Yang DH - Korean J. Intern. Med. (1996)

Bottom Line: Cessation of the oozing did not occur within 3 hours after DDAVP administration in all of the cases. vWF levels and t-PA antigen were significantly increased after DDAVP administration peaked at 30 min for vWF and 60 min for t-PA antigen. t-PA activity increased in 6 cases and euglobulin fibrinolytic activity increased in 7 cases, respectively.DDAVP increased both vWF and t-PA levels and cessation of the oozing from post-operative AV-fistula wounds did not occur within 3 hours after DDAVP administration in all of the cases.These results suggest that the effect of DDAVP should be reassessed in the treatment of uremic bleeding.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Soonchunhyang Hospital, Chunan, Korea.

ABSTRACT

Objectives: This study is designed to evaluate the clinical outcome of uremic bleeding treated with DDAVP. DDAVP was given intravenously in nine ESRD patients who had undergone A/V fistula surgery and showed oozing of the operation site for more than one hour.

Methods: Hemostasis was observed by removing the blood from the wound site with a piece of filter paper for 3 hours after DDAVP administration. vWF, t-PA antigen, t-PA activity, total fibrinolytic activity in euglobulin fraction, fibrinopeptide A and FDP were measured before and after DDAVP administration.

Results: Cessation of the oozing did not occur within 3 hours after DDAVP administration in all of the cases. vWF levels and t-PA antigen were significantly increased after DDAVP administration peaked at 30 min for vWF and 60 min for t-PA antigen. t-PA activity increased in 6 cases and euglobulin fibrinolytic activity increased in 7 cases, respectively. These values fell towards pre-administration levels 120 min after the administration. There was no difference in fibrinopeptide A levels before and after DDAVP administration. FDP became positive in 4 cases after DDAVP administration.

Conclusion: DDAVP increased both vWF and t-PA levels and cessation of the oozing from post-operative AV-fistula wounds did not occur within 3 hours after DDAVP administration in all of the cases. These results suggest that the effect of DDAVP should be reassessed in the treatment of uremic bleeding.

Show MeSH

Related in: MedlinePlus

Individual changes of fibrinolytic activity in euglobulin fraction before and after DDAVP administration.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4532022&req=5

f4-kjim-11-2-145-8: Individual changes of fibrinolytic activity in euglobulin fraction before and after DDAVP administration.

Mentions: Euglobulin Fibrinolytic Activity increased in 7 cases (all except case No; 1, 2) and peaked between 60 min and 90 min (Fig. 4).


Effect of deamino-8-D-arginine desmopressin in uremic bleeding.

Hong SY, Yang DH - Korean J. Intern. Med. (1996)

Individual changes of fibrinolytic activity in euglobulin fraction before and after DDAVP administration.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4532022&req=5

f4-kjim-11-2-145-8: Individual changes of fibrinolytic activity in euglobulin fraction before and after DDAVP administration.
Mentions: Euglobulin Fibrinolytic Activity increased in 7 cases (all except case No; 1, 2) and peaked between 60 min and 90 min (Fig. 4).

Bottom Line: Cessation of the oozing did not occur within 3 hours after DDAVP administration in all of the cases. vWF levels and t-PA antigen were significantly increased after DDAVP administration peaked at 30 min for vWF and 60 min for t-PA antigen. t-PA activity increased in 6 cases and euglobulin fibrinolytic activity increased in 7 cases, respectively.DDAVP increased both vWF and t-PA levels and cessation of the oozing from post-operative AV-fistula wounds did not occur within 3 hours after DDAVP administration in all of the cases.These results suggest that the effect of DDAVP should be reassessed in the treatment of uremic bleeding.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Soonchunhyang Hospital, Chunan, Korea.

ABSTRACT

Objectives: This study is designed to evaluate the clinical outcome of uremic bleeding treated with DDAVP. DDAVP was given intravenously in nine ESRD patients who had undergone A/V fistula surgery and showed oozing of the operation site for more than one hour.

Methods: Hemostasis was observed by removing the blood from the wound site with a piece of filter paper for 3 hours after DDAVP administration. vWF, t-PA antigen, t-PA activity, total fibrinolytic activity in euglobulin fraction, fibrinopeptide A and FDP were measured before and after DDAVP administration.

Results: Cessation of the oozing did not occur within 3 hours after DDAVP administration in all of the cases. vWF levels and t-PA antigen were significantly increased after DDAVP administration peaked at 30 min for vWF and 60 min for t-PA antigen. t-PA activity increased in 6 cases and euglobulin fibrinolytic activity increased in 7 cases, respectively. These values fell towards pre-administration levels 120 min after the administration. There was no difference in fibrinopeptide A levels before and after DDAVP administration. FDP became positive in 4 cases after DDAVP administration.

Conclusion: DDAVP increased both vWF and t-PA levels and cessation of the oozing from post-operative AV-fistula wounds did not occur within 3 hours after DDAVP administration in all of the cases. These results suggest that the effect of DDAVP should be reassessed in the treatment of uremic bleeding.

Show MeSH
Related in: MedlinePlus